The Future of Heart Disease Diagnosis with AI

Why It Matters

The study shows AI can enhance cardiac care while reshaping spending, prompting regulators and insurers to rethink reimbursement models for emerging diagnostic technologies.

Key Takeaways

• FDA approves AI tools via 510(k) using retrospective performance data.
• CMS reimburses only FDA‑cleared AI, focusing on clinical necessity.
• FFRCT adoption increased CCTA use while reducing invasive angiography.
• Overall cardiac testing spend rose despite lower invasive procedure costs.
• Patient outcomes improved modestly, showing clinical value of AI tool.

Summary

The podcast examines a new Health Affairs paper by Dr. Anna Zinc on the real‑world impact of an AI‑driven diagnostic tool, computed‑tomography fractional flow reserve (FFRCT), used alongside cardiac CT imaging. The discussion frames the study within the broader regulatory landscape, noting that more than 1,300 AI applications have FDA clearance, most through the 510(k) pathway based on retrospective performance, while Medicare reimburses only those deemed reasonable and necessary, often relying on peer‑reviewed evidence.

The authors used a difference‑in‑differences design to compare physicians who adopted FFRCT with those who did not. Adoption led to higher use of CCTA and the AI‑generated FFRCT report, a modest decline in invasive coronary angiography, and an overall rise in cardiac testing expenditures because the newer tests are costlier than traditional stress tests. Despite higher spending, the study observed a slight reduction in adverse cardiac events among patients evaluated with the AI tool.

Dr. Zinc highlighted that “the FDA looks for safety and effectiveness through retrospective benchmarks, whereas CMS wants evidence of clinical necessity,” underscoring the tension between rapid innovation and rigorous evaluation. The paper also raised pricing questions, noting current Medicare reimbursement exceeds $1,000 per use and may need adjustment as competition emerges.

The findings suggest AI can improve diagnostic precision and outcomes, but cost offsets are not automatic. Policymakers and payers must develop pricing structures—bundled, subscription, or value‑based—that reflect both clinical benefit and fiscal sustainability as AI tools proliferate across specialties.

Original Description

In this episode of A Health Podyssey, we dig into a real-world study of an FDA‑approved diagnostic AI tool used in cardiac care. Host Rob Lott talks with Dr. Anna Zink about how FFRCT—an AI tool that analyzes heart imaging—can change clinicians’ testing decisions, impact spending, and may improve patient outcomes. We also explore what these findings mean for Medicare reimbursement, FDA oversight, and the future of AI regulation in health care.

If you’re interested in AI in medicine, medical imaging, health policy, or how new technologies affect real patient care, this episode breaks it all down.

---

Visit Health Affairs: http://www.healthaffairs.org

Subscribe and Listen to our Podcasts: https://www.healthaffairs.org/podcasts

Sign up for our free Newsletters: https://www.healthaffairs.org/newsletters